Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| RESMED INCRMD · Entity 2692 | Director · Chairman and CEO | October 07, 2026 | October 08, 2026 |
| ZIMMER BIOMET HOLDINGS, INC.ZBH · Entity 3278 | Director | September 30, 2026 | October 03, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
RESMED INC
Report date October 07, 2026 · Filed October 08, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| ResMed Common StockSEC Table I · non-derivative | Direct | 479,803 |
Ending reported balance
After 2026-10-07 transaction · row 2
2 source rows · reconciled sequenceRow 1 · 2026-10-07 · Exercise / conversion · Acquired 4,991 · Balance 484,794 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Row 2 · 2026-10-07 · Sale · Disposed 4,991 · Balance 479,803 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price. |
| ResMed Common Stock OptionsSEC Table II · derivative / convertible security · Conversion / exercise price $146.34 · Expires 2026-11-21 | Direct | 4,993 |
Reported balance
After 2026-10-07 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-10-07 · Exercise / conversion · Disposed 4,991 · Balance 4,993 F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3: Represents date options first become exercisable. Options vest 1/3 per year |
| ResMed Common StockSEC Table I · non-derivative | IndirectLisette and Michael Farrell Family Trust | 2,090 |
Reported balance
Holding disclosure · report date 2026-10-07 · row 3
Holding and transaction disclosures are not merged.
1 source rowRow 3 · Balance 2,090 |
Filing footnotes · ownership attribution and instrument terms
F1: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024.
F2: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price.
F3: Represents date options first become exercisable. Options vest 1/3 per year
ZIMMER BIOMET HOLDINGS, INC.
Report date September 30, 2026 · Filed October 03, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Phantom Stock UnitsSEC Table II · derivative / convertible security · Conversion / exercise price $89.85 | Direct | 20,073.731 |
Reported balance
After 2026-09-30 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-09-30 · Grant · Acquired 417.363 · Balance 20,073.731 F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors F2: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. |
Filing footnotes · ownership attribution and instrument terms
F1: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors
F2: The Conversion or Exercise Price of Derivative Security is 1-for-1.
F3: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director.
F4: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| October 07, 2026 Filed Oct 8, 2026 21:31 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000085 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 4,993 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year Read SEC document |
| October 07, 2026 Filed Oct 8, 2026 21:31 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,991 | $226.33 | $1,129,637.49 |
DisclosureSEC source: 0000943819-26-000085 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 479,803 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $222.2135 - $227.581. The price reported above reflects the weighted average sale price. Read SEC document |
| October 07, 2026 Filed Oct 8, 2026 21:31 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000085 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 484,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| September 30, 2026 Filed Oct 3, 2026 00:24 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 417.363 | $0.00 Strike: $89.85 | $0.00 |
DisclosureSEC source: 0001485164-26-000010 · form4-10022026_081058.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,073.731 Underlying: Common Stock · 417.363 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 49.652 phantom stock units accrued on July 31, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 10:40 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000052 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 9,984 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 10:40 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,991 | $222.44 | $1,110,190.55 |
DisclosureSEC source: 0000943819-26-000052 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,256 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $220.680 - $225.390. The price reported above reflects the weighted average sale price. Read SEC document |
| September 08, 2026 Filed Sep 10, 2026 10:40 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000052 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| August 14, 2026 Filed Oct 2, 2026 00:19 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 13,547 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-26-000075 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 479,803 F1 · kind: Represents performance-based restricted stock units granted on November 20, 2025. The shares were earned on August 14, 2026, when the compensation committee certified that the performance metrics were met. Stock units vest 1/3 each year on the anniversary of the grant. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 10:30 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000043 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 14,975 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 10:30 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,991 | $205.69 | $1,026,596.29 |
DisclosureSEC source: 0000943819-26-000043 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,256 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $202.410 - $204.160. The price reported above reflects the weighted average sale price. Read SEC document |
| August 07, 2026 Filed Aug 11, 2026 10:30 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000043 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,247 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 11:40 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000038 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 19,966 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 11:40 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,991 | $218.55 | $1,090,770.57 |
DisclosureSEC source: 0000943819-26-000038 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $216.772 - $219.700. The price reported above reflects the weighted average sale price. Read SEC document |
| July 07, 2026 Filed Jul 9, 2026 11:40 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000038 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| June 30, 2026 Filed Jul 2, 2026 20:21 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 432.776 | $0.00 Strike: $86.65 | $0.00 |
DisclosureSEC source: 0001485164-26-000008 · form4-07022026_080717.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,606.716 Underlying: Common Stock · 432.776 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 18:26 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000035 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 24,957 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 18:26 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,991 | $193.96 | $968,064.34 |
DisclosureSEC source: 0000943819-26-000035 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,256 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $192.605 - $194.715. The price reported above reflects the weighted average sale price. F3 · balance_after: Includes 32.671 shares of Resmed stock purchased on April 30, 2026 through the Resmed Employee Stock Purchase Plan. Read SEC document |
| June 08, 2026 Filed Jun 9, 2026 18:26 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000035 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:14 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantRestricted Stock Units · Derivative | 1,517.274 | $0.00 | $0.00 |
DisclosureSEC source: 0001485164-26-000006 · form4-05272026_080533.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 13,757 Underlying: Common Stock · 1,517.274 shares Expires not disclosed F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F5 · derivative.exercise_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination as a Director or (2) the date that is three years after the grant date. F5 · derivative.expiration_date: The Restricted Stock Units are immediately 100% vested and will be subject to mandatory deferral until the later of (1) the reporting person's termination as a Director or (2) the date that is three years after the grant date. F6 · balance_after: Includes Restricted Stock Units granted in prior years that are subject to different mandatory deferral periods. Read SEC document |
| May 22, 2026 Filed May 27, 2026 20:14 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 875.35 | $0.00 Strike: $85.68 | $0.00 |
DisclosureSEC source: 0001485164-26-000006 · form4-05272026_080533.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,173.94 Underlying: Common Stock · 875.35 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in shares of Company common stock within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 53.557 phantom stock units accrued on April 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| May 07, 2026 Filed May 11, 2026 11:33 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000030 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 29,948 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| May 07, 2026 Filed May 11, 2026 11:33 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,991 | $207.82 | $1,037,232.61 |
DisclosureSEC source: 0000943819-26-000030 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $206.45 - $210.47. The price reported above reflects the weighted average sale price. Read SEC document |
| May 07, 2026 Filed May 11, 2026 11:33 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000030 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 15:44 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000021 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 34,939 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 15:44 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,991 | $225.50 | $1,125,486.47 |
DisclosureSEC source: 0000943819-26-000021 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $222.5643 - $227.96. The price reported above reflects the weighted average sale price. Read SEC document |
| April 07, 2026 Filed Apr 9, 2026 15:44 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000021 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| March 31, 2026 Filed Apr 2, 2026 20:13 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 420.97 | $0.00 Strike: $89.08 | $0.00 |
DisclosureSEC source: 0001485164-26-000004 · form4-04022026_080452.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 18,245.033 Underlying: Common Stock · 420.97 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 48.381 phantom stock units accrued on January 30, 2026 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 12:29 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000016 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 39,930 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 12:29 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,991 | $251.03 | $1,252,901.71 |
DisclosureSEC source: 0000943819-26-000016 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $246.83 - $253.09. The price reported above reflects the weighted average sale price. Read SEC document |
| March 09, 2026 Filed Mar 11, 2026 12:29 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000016 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 18:33 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000011 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 44,921 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 18:33 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,991 | $273.78 | $1,366,436.48 |
DisclosureSEC source: 0000943819-26-000011 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $270.25 - $276.35. The price reported above reflects the weighted average sale price. Read SEC document |
| February 09, 2026 Filed Feb 10, 2026 18:33 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000011 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 20:23 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-26-000003 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 49,912 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 20:23 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,991 | $248.46 | $1,240,065.36 |
DisclosureSEC source: 0000943819-26-000003 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $246.801 - $249.969. The price reported above reflects the weighted average sale price. Read SEC document |
| January 07, 2026 Filed Jan 8, 2026 20:23 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-26-000003 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| December 31, 2025 Filed Jan 5, 2026 21:04 UTC | ZIMMER BIOMET HOLDINGS, INC. ZBH · Entity 3278 | GrantPhantom Stock Units · Derivative | 415.144 | $0.00 Strike: $90.33 | $0.00 |
DisclosureSEC source: 0001485164-26-000002 · form4-01052026_090157.xml · derivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,775.682 Underlying: Common Stock · 415.144 shares Expires not disclosed F1 · security: The phantom stock units were accrued under the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. F2 · derivative.exercise_price: The Conversion or Exercise Price of Derivative Security is 1-for-1. F3 · derivative.exercise_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F3 · derivative.expiration_date: Units are to be settled in cash in a lump sum within sixty days after cessation of the reporting person's service as a Director. F4 · balance_after: Includes 41.590 phantom stock units accrued on October 31, 2025 under the dividend reinvestment provision of the Zimmer Biomet Holdings, Inc. Deferred Compensation Plan for Non-Employee Directors. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 20:17 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 4,991 | $0.00 Strike: $146.34 | $0.00 |
DisclosureSEC source: 0000943819-25-000187 · form4.xml · derivative · entry 4 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 54,903 Underlying: ResMed Common Stock · 4,991 shares Expires 2026-11-21 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 20:17 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 4,991 | $251.41 | $1,254,795.79 |
DisclosureSEC source: 0000943819-25-000187 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 466,223 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F2 · price: This transaction was executed in multiple trades at prices ranging from $249.63 - $255.775. The price reported above reflects the weighted average sale price. Read SEC document |
| December 08, 2025 Filed Dec 9, 2025 20:17 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 4,991 | $146.34 | $730,382.94 |
DisclosureSEC source: 0000943819-25-000187 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 471,214 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
| November 24, 2025 Filed Nov 26, 2025 20:29 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock Options · Derivative | 33,288 | $250.52 Strike: $250.52 | $8,339,309.76 |
DisclosureSEC source: 0000943819-25-000183 · form4.xml · derivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,288 Underlying: ResMed Common Stock · 33,288 shares Expires 2032-11-11 F1 · derivative.exercise_date: Represents the date on which options first become exercisable. The options vest in three equal annual installments commencing on November 11, 2026. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 15:42 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 7,297 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000170 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 466,223 F2 · kind: Disposition to issuer for tax withholding on vesting of performance-based restricted stock units granted on November 16, 2022. Read SEC document |
| November 20, 2025 Filed Nov 24, 2025 15:42 UTC | RESMED INC RMD · Entity 2692 | GrantResMed Common Stock | 13,551 | $0.00 | $0.00 |
DisclosureSEC source: 0000943819-25-000170 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 473,520 F1 · kind: Represents performance-based restricted stock units granted on November 16, 2022. The shares were earned on November 20, 2025, when the compensation and leadership development committee certified that the performance metrics were met. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:37 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 2,205.697 | $250.10 | $551,644.82 |
DisclosureSEC source: 0000943819-25-000116 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 459,969 F3 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2024. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:37 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 3,459.325 | $250.10 | $865,177.18 |
DisclosureSEC source: 0000943819-25-000116 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 462,175 F2 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2023. Read SEC document |
| November 11, 2025 Filed Nov 13, 2025 22:37 UTC | RESMED INC RMD · Entity 2692 | Tax withholdingResMed Common Stock | 2,231.545 | $250.10 | $558,109.40 |
DisclosureSEC source: 0000943819-25-000116 · form4.xml · nonDerivative · entry 1 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 465,634 F1 · kind: Disposition to issuer for tax withholding on vesting of Restricted Stock Units granted on 11/16/2022. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 00:07 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 7,028 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000095 · form4.xml · derivative · entry 6 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 0 Underlying: ResMed Common Stock · 7,028 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F4 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 00:07 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock Options · Derivative | 983 | $0.00 Strike: $101.64 | $0.00 |
DisclosureSEC source: 0000943819-25-000095 · form4.xml · derivative · entry 5 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 7,028 Underlying: ResMed Common Stock · 983 shares Expires 2025-11-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F4 · derivative.exercise_date: Represents date options first become exercisable. Options vest 1/3 per year. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 00:07 UTC | RESMED INC RMD · Entity 2692 | SaleResMed Common Stock | 8,011 | $249.75 | $2,000,772.89 |
DisclosureSEC source: 0000943819-25-000095 · form4.xml · nonDerivative · entry 3 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 467,866 F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. F3 · price: This transaction was executed in multiple trades at prices ranging from $248.13 - $251.46. The price reported above reflects the weighted average sale price. Read SEC document |
| November 07, 2025 Filed Nov 11, 2025 00:07 UTC | RESMED INC RMD · Entity 2692 | Exercise / conversionResMed Common Stock | 7,028 | $101.64 | $714,325.92 |
DisclosureSEC source: 0000943819-25-000095 · form4.xml · nonDerivative · entry 2 Farrell Michael J. · CIK 0001485164 · Director · Chairman and CEO 10b5-1 filing: Plan reported Ownership: Direct Disclosed balance after: 475,877 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · kind: The transaction was conducted under a Rule 10b5-1 plan adopted October 31, 2024. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.